Dopamine agonists are commonly used in the treatment of Parkinson’s disease (PD) because of their efficacy and their established safety and tolerability profile. Dopamine agonists, such as REQUIP, can effectively control Parkinson’s disease symptoms in certain patient populations.1
Use of REQUIP in Parkinson's Disease:
- Effectively controls Parkinson’s disease symptoms1
- Maintains patient activities of daily living (ADLs) 1
- Is associated with a reduced risk of dyskinesia vs L-dopa1
Parkinson’s Disease: A Long-term Condition
Most patients diagnosed with Parkinson’s disease will live with the disease for many years. Long-term treatment of PD is associated with motor complications, such as dyskinesia.3
Risk factors for dyskinesia and motor fluctuations include higher doses of
Nearly 40% of patients suffer from motor complications within 5 years of treatment with L-dopa.3
